Masterclass | Sequencing therapies in cGvHD

Corticosteroids have remained the standard first-line treatment for chronic graft-versus-host disease (cGvHD) over the past four decades; however, there is no consensus on the optimal sequencing after steroid failure.^1–4 In the absence of a defined treatment algorithm, treatment selection for steroid-refractory cGvHD (SR-cGvHD) is highly individualized and guided by both patient- and ​treatment-related factors.² U.S. Food and Drug Administration (FDA)-approved options for SR-cGvHD include ibrutinib, ruxolitinib, belumosudil, and axatilimab.⁵ Several emerging agents and combination strategies are also under investigation and may further shape the treatment landscape. 

The GvHD Hub spoke with Daniel Wolff, Corey Cutler, and Robert Zeiser to gain their expert insights regarding sequencing therapies in cGvHD, including factors influencing the decision to switch from first- to second-line therapy, approaches to later-line sequencing, and how emerging therapies and combination strategies may reshape future treatment sequencing. 

This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.